BRCA1 and neoplasm: Although distinct differences may exist depending on populations, races, and tumor types [24], Marabelli et al. [25] reported that far fewer men than women (less than 1:10) were tested for BRCA1/2 mutations in European countries and that broader genetic data on males may contribute to the diagnosis and management of patients and increase treatment and clinical trial options.